N-(4-羟基苯基)-N-甲基乙酰胺 | 579-58-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(4-羟基苯基)-N-甲基乙酰胺
• 英文名称: N-methyl-(4-acetamido)phenol
• 英文别名: N-methylacetaminophen；N-(4-hydroxyphenyl)-N-methylacetamide；N-Methyl-p-acetamidophenol；N-Methyl-N-acetyl-p-amino-phenol；4-(N-acetyl-N-methylamino)phenol
• CAS: 579-58-8
• 化学式: C₉H₁₁NO₂
• mdl: MFCD00872063
• 分子量: 165.192
• InChiKey: STOAGEBURGENGQ-UHFFFAOYSA-N

物化性质

• 熔点：
  242 °C
• 沸点：
  317.2±25.0 °C(Predicted)
• 密度：
  1.184±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  N-(4-羟基苯基)-N-甲基乙酰胺 在 乙醇 、 硫酸 、 镍 作用下， 生成 trans-4-(Methylamino)cyclohexanol
  参考文献：
  名称：

  Process for the manufacture of cyclohexanols

  摘要：

  公开号：

  US02152960A1
• 作为产物：
  描述：

  对甲氨基酚 在 三乙胺 、 sodium hydroxide 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 30.0h， 生成 N-(4-羟基苯基)-N-甲基乙酰胺
  参考文献：
  名称：

  哌啶（哌嗪）-酰胺取代的衍生物作为多靶点抗精神病药的合成和药理评价。

  摘要：

  我们报告了与多巴胺和5-羟色胺受体的多配体方法一系列新型酰胺-哌啶（哌嗪）衍生物的优化。在衍生物中，化合物11显示出高亲和力为d 2，5-HT 1A和5-HT 2A受体，但低亲和性对5-HT 2C和组胺H 2 1受体和人ether-A-GO-中间人相关基因（hERG）通道。体内化合物11即使在测试的最高剂量下，阿扑吗啡引起的攀爬，MK-801引起的活动过度和DOI引起的头部抽搐也没有明显的僵直。另外，它在CAR测试中表现出抑制作用。此外，在一个新颖的物体识别任务中，它显示了识别属性。因此，化合物11是有希望的候选多靶点抗精神病药。

  DOI：

  10.1016/j.bmcl.2020.127506

文献信息

• [EN] LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS<br/>[FR] PROMÉDICAMENTS LIPIDIQUES ORIENTANT VERS LE SYSTÈME LYMPHATIQUE
  申请人：ARIYA THERAPEUTICS INC

  公开号：WO2019046491A1

  公开（公告）日：2019-03-07

  The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a provided lipid prodrug or a pharmaceutical composition thereof.

  本发明提供了淋巴系统定向脂质前药，其制药组合物，制备这种前药和组合物的方法，以及改善作为脂质前药一部分的治疗剂的生物利用度或其他性质的方法。本发明还提供了治疗疾病、紊乱或症状的方法，包括向需要的患者施用所提供的脂质前药或其制药组合物。
• Nickel-catalyzed reductive cleavage of aryl–oxygen bonds in alkoxy- and pivaloxyarenes using hydrosilanes as a mild reducing agent
  作者：Mamoru Tobisu、Ken Yamakawa、Toshiaki Shimasaki、Naoto Chatani

  DOI：10.1039/c0cc05169a

  日期：——

  A nickel-catalyzed reductive deoxygenation of aryl alkyl ethers and aryl pivalates has been developed. Hydrosilanes serve as a mild reducing agent. The present protocol allows the use of a pivalate group as a robust and traceless steering group in arene functionalization reactions.

  开发了一种镍催化的芳基烷基醚和芳基三甲基酯的去氧还原反应。氢硅烷作为温和的还原剂。目前的方案允许在芳烃功能化反应中使用三甲基酯基团作为强健且无痕的导向基团。
• [EN] NEW ISOINDOLINE OR ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] NOUVEAUX COMPOSÉS ISOINDOLINE OU ISOQUINOLÉINE, PROCÉDÉ POUR LEUR PRÉPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：SERVIER LAB

  公开号：WO2015011164A1

  公开（公告）日：2015-01-29

  Compounds of formula (I): (I) wherein Het, R3, R4, R5, R7, R8, R9, T, p, p', q, and q' are as defined in the description are pro-apoptotic agents useful in the treatment of cancers and of auto-immune and immune system diseases.

  式(I)的化合物：其中Het、R3、R4、R5、R7、R8、R9、T、p、p'、q和q'的定义如描述中所定义，是在治疗癌症以及自身免疫和免疫系统疾病中有用的促凋亡剂。
• Substituted 4-amino-7H-pyrrolo [2,3,-d]-pyrimidines as PTK inhibitors
  申请人：BASF Aktiengesellschaft

  公开号：US06001839A1

  公开（公告）日：1999-12-14

  Compounds of formula I ##STR1## including pharmaceutically acceptable salts thereof in which R.sub.1 represents hydrogen, 2-phenyl-1,3-dioxan-5-yl, a C.sub.1-6 alkyl group, a C.sub.3-8 cycloalkyl group, a C.sub.5-7 cycloalkenyl group or an (optionally substituted phenyl)C.sub.1-6 alkyl group wherein the alkyl, cycloalkyl and cycloalkenyl groups are optionally substituted by one or more groups of formula OR.sub.A in which R.sub.A represents H or a C.sub.1-6 alkyl group provided that a group of formula OR.sub.A is not located on the carbon attached to nitrogen; R.sub.2 represents hydrogen, a C.sub.1-6 alkyl group, a C.sub.3-8 cycloalkyl group, halo, hydroxy, an (optionally substituted phenyl)C.sub.1-6 alkyl group, optionally substituted phenyl or R.sub.4 ; and R.sub.3 represents a group of formula (a) ##STR2## in which the phenyl ring is additionally optionally substituted and A represents NH, O, NHSO.sub.2, SO.sub.2 NH, a C.sub.1-4 alkylene chain, NHCO, NHCO.sub.2, CONH, NHCONH, CO.sub.2 or S(O).sub.p in which p is 0, 1 or 2, or A is absent and R.sub.5 is attached directly to the phenyl ring; and R.sub.5 represents optionally substituted phenyl and, additionally, when A is absent R.sub.5 represents a) a phthalimido group optionally substituted by halo or b) a pyrazolylamino group in which the pyrazole ring is optionally substituted by one or more of the following: hydroxy or optionally substituted phenyl; R.sub.4 represents a heterocyclic group; are described which are useful in treating proliferative diseases and disorders of the immune system in mammals. Processes to prepare these compounds and pharmaceutical compositions containing these compound are also described.

  化学式I的化合物包括其药学上可接受的盐，其中R.sub.1代表氢，2-苯基-1,3-二噁烷-5-基，C.sub.1-6烷基，C.sub.3-8环烷基，C.sub.5-7环烯基或（可选择取代的苯基）C.sub.1-6烷基，其中烷基，环烷基和环烯基基团可选择地被一个或多个OR.sub.A的基团取代，其中R.sub.A代表H或C.sub.1-6烷基基团，前提是OR.sub.A的基团不位于连接氮的碳上；R.sub.2代表氢，C.sub.1-6烷基，C.sub.3-8环烷基，卤素，羟基，（可选择取代的苯基）C.sub.1-6烷基，可选择取代的苯基或R.sub.4；R.sub.3代表下列式(a)的基团：其中苯环另外可选择地被取代，A代表NH，O，NHSO.sub.2，SO.sub.2 NH，C.sub.1-4烷基链，NHCO，NHCO.sub.2，CONH，NHCONH，CO.sub.2或S(O).sub.p，其中p为0, 1或2，或A不存在且R.sub.5直接连接到苯环；R.sub.5代表可选择取代的苯基，并且当A不存在时，R.sub.5代表a）可选择地被卤素取代的邻苯二甲酰亚胺基团或b）可选择地被下列之一取代的吡唑基氨基团：羟基或可选择取代的苯基；R.sub.4代表杂环基团；这些化合物用于治疗哺乳动物的增殖性疾病和免疫系统紊乱。还描述了制备这些化合物的过程和含有这些化合物的药物组合物。
• Fungicidal 2-aryl-2-cyano-2-(aryloxyalkyl)ethyl-1,2-4-triazoles
  申请人：Rohm and Haas Company

  公开号：US05527816A1

  公开（公告）日：1996-06-18

  2-aryl-2-cyano-2-(aryloxyalkyl)ethyl-1,2,4-triazoles of the formula ##STR1## wherein Ar.sup.1 and Ar.sup.2 are optionally substituted aryl groups which may or may not be different, R is hydrogen or alkyl, n is an integer of at least one, and the agronomically acceptable enantiomorphs, acid addition salts and metal salt complexes thereof, compositions containing these compounds and their uses as fungicides, particularly against phytopathogenic fungi.

  该公式为2-芳基-2-氰基-2-(芳氧基烷基)乙基-1,2,4-三唑，其中Ar.sup.1和Ar.sup.2是可选择取代的芳基，可能相同也可能不同，R为氢或烷基，n为至少为一的整数，以及其农业上可接受的对映体、酸盐和金属盐络合物，含有这些化合物的组合物以及它们作为杀菌剂的用途，特别是用于对抗植物病原真菌。

表征谱图